| 1 |
Adrienne Edkins
|
a.edkins@ru.ac.za
|
South Africa |
Host-Virus Interactions in KSHV-Related Malignancies: Evaluating the Role of STIP1 as a Therapeutic Target |
Biology (Genomic&Transcriptomics, CRISPR/Cas9, RNAi knockdown, Target deconvolution; MoA determination); Toxicology (in vitro) |
We study protein homeostasis in the context of health and disease. The aim of our research is to understand the molecular mechanisms of the processes that underpin proteostasis (translation, folding and degradation) with an emphasis on molecular chaperone function. We study this across a range of comparative models e.g. normal versus cancerous cells or pathogen versus host systems in order to understand how chaperone systems regulate healthy or diseased states. We subsequently apply this information to identify therapeutic opportunities (e.g. drug targets, inhibitors or biological assays). |
TB; Viral assays; AMR; TB, E. coli, cancer cell line models, KSHV |
|
TB, E. coli, cancer cell line models, KSHV |
Cell viability (MTT, AlamarBlue, etc.);Hepatotoxicity (HepG2 cells) (In vitro);Cytotoxicity (cancer vs. normal cells) (In vitro) |
Range of cancer cell line models (cervical, breast, lung and colon). VERO and HepG2 |
|
Michael Obinna Okpara, Richwell Mhlanga, Kelly Schwarz, Steven Raubenheimer, Anita Ndabeni, Teboho Satekge , Boipelo Mongale |
|
| 2 |
Amanda Rousseau
|
Amanda.Rousseau@wits.ac.za
|
South Africa |
|
Chemistry |
Organic synthesis of compounds with potential medicinal properties, specifically looking at malaria and antimicrobial compounds. |
|
|
|
|
|
|
|
|
| 3 |
Arnold Donkor Forkuo |
afdonkor.chs@knust.edu.gh
|
Ghana |
|
Genomics and transcriptomics; CRISPR/Cas9; Natural products chemistry; Pharmacology (ADME/Tox); |
Pharmacology(ADME/DMPK) and toxicology . There is a group in my department also working on Zebra fish research, CNS pharmacology and behavioral pharmacology. |
Malaria; AMR |
|
|
|
|
|
|
|
| 4 |
Candice Soares de Melo |
candice.soaresdemelo@uct.ac.za
|
South Africa |
|
Medicinal chemistry |
|
TB: Malaria; AMR; NTDs; Viral assays; Other |
|
Malaria (chloroquine sensitive and resistant), TB (drug sensitive and resistant strain), Most neglected diseases (schistosomiasis, filariasis, onchocerciasis, buruli ulcer, helminthese etc) |
Hepatotoxicity (HepG2 cells) (In vitro);Acute toxicity (In vivo);Sub-acute and chronic studies (In vivo);Reproductive toxicity (In vivo);Developmental toxicity (In vivo);Neurotoxicity and behavioural testing (In vivo) |
|
|
|
|
| 5 |
Collen Masimirembwa |
cmasimirembwa@aibst.edu.zw
|
Zimbabwe |
Pan-African DMPK Centre of Excellence at the African Institute of Biomedical Science and Technology (AiBST) |
Drug Metabolism and Pharmacokinetics |
|
|
|
|
|
|
|
|
|
| 6 |
Dina Coertzen |
dina.coertzen@up.ac.za
|
South Africa |
|
Malaria biology; Screening |
|
|
|
|
|
|
|
|
|
| 7 |
Dinkorma Ouologuem |
dinkorma@gmail.com
|
Mali |
|
Malaria biology; Parasitology |
|
|
|
|
|
|
|
|
|
| 8 |
Edwin Murungi |
eddkimm@gmail.com
|
Kenya |
|
Genomics and transcriptomics; Natural Products (Extraction&Fractionation); Molecular docking; Bioinformatics; |
We undertake early stage computational studies to identify putative hit compounds and decode their target binding in order to guide medicinal chemistry experiments. We are currently involved in a tuberculosis (TB) drug discovery project and a non-hormonal contraceptives project. |
TB; non-hormonal contraceptives |
|
|
|
|
|
|
|
| 9 |
Elizabeth Kigondu |
ekigondu@kemri.go.ke
|
Kenya |
|
Biology (Genomics&Transcriptomics…; Mechanistic and Functional Biology Assays; others); Natural Products Chemistry; Toxicology; DMPK (PK/PD); Formulation Development |
My institute KEMRI is composed of Centers conducting human health research along seven thematic areas that include: Infectious and parasitic diseases, non-communicable diseases, natural products and drug research, one health approach, public health and health systems, sexual reproductive, adolescent and child health and biotechnology research progams. |
TB: Malaria; NTDs; Viral assays; AMR |
Malaria;Tuberculosis (TB);Neglected Tropical Diseases (please specify, e.g., Schistosomiasis, Leishmaniasis, Onchocerciasis, Trypanosomiasis, Helminthiases);Viral assays (e.g., HIV, SARS-CoV-2, others – please specify);Bacterial assays (e.g., AMR-related);Other disease areas (e.g., cancer, neurodegenerative, metabolic, or cardiovascular assays) |
Malaria (sensitive and resistant strains); TB (lab adapted, resistant and clinical isolates); NTDs (schistosomiasis clinical strains, leishmaniasis lab adapted and clinical strains); viral (HIV lab adapted, SARS-CoV-2 clinical isolates, aboviruses clinical isolates); bacterial (array of lab adapted and clinical isolates); other diseases (cancer, diabetes, inflammatory diseases, sickle cell, reproductive health, wound healing, metabolic) |
Cell viability (MTT, AlamarBlue, etc.);Cytotoxicity (cancer vs. normal cells) (In vitro);Haemolysis assays (In vitro);Genotoxicity (Ames, micronucleus tests) (In vitro);Acute toxicity (In vivo);Sub-acute and chronic studies (In vivo);Reproductive toxicity (In vivo);Developmental toxicity (In vivo);Neurotoxicity and behavioural testing (In vivo) |
1-2 weeks (with repeats) for in vitro toxicity studies and 1-9 months (with repeats) for in vivo safety studies, depending on the assay. |
https://kce.kemri.go.ke/ |
|
|
| 10 |
Erick Strauss |
estrauss@sun.ac.za
|
South Africa |
Pursuing Targeted Protein Degradation as a New Strategy for Antituberculosis Drug Development |
Biology (Elaborate range of Mechanistic and Functional Assays); Chemistry; Natural Products Chemistry (Extraction, purification, characterization); Toxicology (in vitro); Computational and Bioinformatics |
Antimicronbial drug development; MoA studies, Target validation |
TB: Malaria: AMR |
Malaria;Tuberculosis (TB);Bacterial assays (e.g., AMR-related);Other disease areas (e.g., cancer, neurodegenerative, metabolic, or cardiovascular assays) |
Drug-sensitive and resistant strains, clinical isolates for bacteria and malaria parasites. Several cancer cell lines. Autophagy assays. |
Cell viability (MTT, AlamarBlue, etc.);Hepatotoxicity (HepG2 cells) (In vitro);Cytotoxicity (cancer vs. normal cells) (In vitro) |
|
https://acti.org.za/ |
Tiaan Olivier, Leandi van der Westhuizen, Ash Bhana, Tim Kotzé |
|
| 11 |
Fabrice Boyom |
fabrice.boyom@fulbrightmail.org
|
Cameroon |
|
Chemistry (Organic synthesis); Natural products; Mechanistic and Functional Biology (Resistance profiling, drug synergy/antagonism,time-kill kinetics) |
The Antimicrobial & Biocontrol Agents Unit (AmBcAU) and the Advanced Research & Health Innovation Hub (ARHIH) conduct cutting-edge research at the early stages of drug discovery, with a strong focus on infectious diseases of major public health concern. Our work spans malaria and allied neglected tropical diseases (NTDs), including human African trypanosomiasis (HAT), leishmaniasis, and Buruli ulcer (BU), as well as bacterial and fungal infections. In addition, we are actively engaged in antimicrobial stewardship (AMS) research targeting priority Gram-negative bacteria, in alignment with WHO’s critical AMR pathogen list. By combining expertise in phenotypic screening, natural product discovery, and translational microbiology, we aim to deliver innovative therapeutic leads that address both endemic tropical diseases and the global threat of antimicrobial resistance. |
TB; AMR; Malaria; NTDs |
Malaria;Tuberculosis (TB);Bacterial assays (e.g., AMR-related);Other disease areas (e.g., cancer, neurodegenerative, metabolic, or cardiovascular assays) |
Plasmodium falciparum (panel of sensitive and resistant lab strains, clinical isolates); Leishmania spp (visceral and cutaneous leishmaniasis lab strains); Trypanosoma spp (HAT and AAT, T. cruzi); Entamoeba histolytica— Amoebiasis agent; Toxoplasma gondii— Toxoplasmosis agent; AMR (Drug-sensitive & resistant bacterial strains, clinical isolates—e.g., Carbapenemase-producing K. pneumoniae, Mycobacterium ulcerans—Buruli ulcer agent, etc.); WHO priority fungal pathogens (e.g., Candida auris). |
Cell viability (MTT, AlamarBlue, etc.);Hepatotoxicity (HepG2 cells) (In vitro);Cytotoxicity (cancer vs. normal cells) (In vitro);Haemolysis assays (In vitro);Acute toxicity (In vivo);Sub-acute and chronic studies (In vivo) |
HepG2, Vero, Raw264.7/THP-1, PC-3/DU145 (prostate cancer), MCF-7 (breast cancer): 40-50 samples/week |
|
|
|
| 12 |
Fidele Ntie-Kang |
fidele.ntie-kang@ubuea.cm
|
Cameroon |
Building a Natural Product Library |
Biology (RNAi knockdown); Chemistry (Organic; Organometallic; Med Chem); Natural Products Chemistry; Toxicology; Docking and Bioniformatics |
We are responsible for building the African Natural Products Database and and have ongoing investigations of small molecules targeting antivirals (HIV, SARS-CoV-2, Mpox, etc) and collaborate in other NTDs like cryptosporidiosis, schistosomiasis and onchocerciases and cancer (investigate Aurora A kinase inhibitors), etc. We conduct virtual screening for hit identification and also carry our fragment-based drug discovery of pseudo-natural products (i.e. synthetic compounds based on natural product fragments), etc. |
Malaria; Viral assays |
Malaria;Viral assays (e.g., HIV, SARS-CoV-2, others – please specify);Other disease areas (e.g., cancer, neurodegenerative, metabolic, or cardiovascular assays) |
HIV latency-reversal using J-lat cell based assay, Onchocerciasis, SARS-CoV-2 spike/ACE2 inhibitory assay, ACE inhibition for testing anti-hypertensive compounds |
|
LLC-MK2 cells plated on 96-well plates (10 96-well plates at a time), incubated for 72 aours, followed by MTT analysis |
www.ub-cedd.org |
Joel Onoja (PhD, postdoc), Smith B. Babiaka (PhD, postdoc), Fritz Mukow Nsanyi (MSc, PhD Candidate), Chantal Emade Nkwelle (MSc, PhD Candidate), Jude Y. Betow (MSc, PhD Candidate & Part-time Lab Assistant), Ariane T. Ndi (MSc, Lab Assistant), Clovis S. Metuge (MSc, Lab Assistant) |
|
| 13 |
Fortunate Mokoena |
Fortunate.Mokoena@nwu.ac.za
|
South Africa |
|
Biology (Genomics&Transcriptomics; Proteomics; Target deconvolution); Mechanistic and Functional Biology Assays (MoA, Resistance profiling, Time-kill kinetics); Bioinformatics (Computational) |
Target based drug discovery focusing on Hsp90 where computational tools are used to design selective molecules which are evaluated for anti-Plasmodium, direct inhibition of target and cytotoxicity assays. If molecules exhibit desirable effect then subjected to ADME studies. We also look at phenotypic screening of drug resistant Klebsiella strains against libraries of chemically diverse compounds followed by more of action studies and evaluation of broad spectrum activity against both field, clinical and ESKAPE pathogens. |
AMR |
Bacterial assays (e.g., AMR-related) |
Laboratory strains (commercially available), field and clinical isolates of ESKAPE pathogens |
|
|
|
|
|
| 14 |
Gabriel Mashabela |
gabrielm@sun.ac.za
|
South Africa |
|
Biology |
|
|
|
|
|
|
|
|
|
| 15 |
Grace Mugumbate |
mugumbateg@staff.msu.ac.zw
|
Zimbabwe |
|
Chemistry (Organic synthesis and Med Chem); Natural Products; Modelling and Computational, Bioinformatics |
Computer - aided drug discovery (https://ww5.msu.ac.zw/drug-discovery-research-group/home/) |
|
|
|
|
|
https://ww5.msu.ac.zw/ |
|
|
| 16 |
Greg Basarab |
greg.basarab@uct.ac.za
|
USA |
|
Medicinal chemistry |
|
|
|
|
|
|
|
|
|
| 17 |
Iruka Okeke |
iruka.n.okeke@gmail.com
|
Nigeria |
|
Biology (Genomic&transcriptomics, Resistance generation and mapping, mutant library screening, "Other"); Mechanism of Action, Drug synergy or antagonism; Bioninformatics (genomics/proteomics); High performance computing cluster |
Our research group at the University of Ibadan, Nigeria, uses microbiology, genetic and genomic methods to investigate the mechanisms bacteria use to colonize humans, cause disease and gain drug resistance. Our antimicrobial resistance work elucidates the genetic basis for antimicrobial resistance (AMR), epidemiology and ecology of bacterial pathogens in Nigeria and other African settings. We support the Nigeria Centre for Disease Control and Prevention by providing genomic services to its AMR surveillance system. We additionally use the sequences generated to address research questions around fundamental biology and applications for diagnostic and therapeutic intervention tool discovery. Our primary focus is enteric Gram negative organisms but we also study other pathogens that cause systemic infections and diarrheal disease. |
AMR |
Bacterial assays (e.g., AMR-related) |
Aerobic/ Facultative bacteria. Resources for culture, molecular biology and genomics. Strain/genome collections from National surveillance and research studies for most priority bacterial pathogens (excluding respiratory pathogens), other aerobic opportunistic bacteria, Salmonella, diarrheagenic E. coli. Resources for anaerobic bacteria and BSL2 genetics currently under construction. |
|
|
|
|
|
| 18 |
Janine Scholefield |
jscholefield@csir.co.za
|
South Africa |
|
Physiologically relevant cellular models |
|
|
|
|
|
|
|
|
|
| 19 |
John Igoli |
igolij@gmail.com
|
Nigeria |
|
Phytochemistry (natural products) |
Isolation and characterization of pure natural compounds for assay against malaria, TB, parasitic and other NTDs. |
|
|
|
|
|
|
|
|
| 20 |
Kelly Chibale |
k.chibale@uct.ac.za
|
South Africa |
|
Director, H3D and H3D Foundation |
|
|
|
|
|
|
|
|
|
| 21 |
Laurent Dembele |
laurent@icermali.org
|
Mali |
|
Malaria biology, cell culture, schistosomes culture |
|
|
|
|
|
|
|
|
|
| 22 |
Liezl Krugmann |
liezl.gibhard@uct.ac.za
|
South Africa |
|
Pharmacology |
|
|
|
|
|
|
|
|
|
| 23 |
Lyn-Marié Birkholtz |
lbirkholtz@sun.ac.za
|
South Africa |
Discovery of novel antimalarial lead candidates in Africa (co-PI): Aurora Kinase Inhibitors as Multistage Active Antimalarials; PROTACs as Resistance-Resistant Antimalarial Candidates |
Chemistry; Biology; Natural Products |
My work focus on antimalarial malaria drug discovery. I integrate a deep understanding of malaria parasite biology in relation to drug discovery and investigate the physiology, biochemistry, and pharmacology of malaria parasites to identify biochemical distinctions between the parasite and the human host, thereby designing novel antimalarial drugs. I spearhead the translation of this information to support malaria elimination strategies by discovering novel transmission-blocking antimalarials. I have a fully integrated biology platform for the evaluation of antimalarial compounds including in vitro sensitivity (lab and clinical isolates), resistance indicators (MIR, in vitro selections), counterscreening, rate and stage and MoA (target ID through transcriptomics, chemical proteomics, morphological fingerprinting and AI modelling). I direct a Global Testing Centre for the Medicines for Malaria Venture (MMV, Switzerland) to evaluate stage-specific gametocytocidal drugs for MMV projects.. |
Malaria; AMR; Viral |
|
Malaria - full panels of drug sensitive & resistant lines, clinical isolates. Viral is HIV assays under Dr Gama; bacterial is AMR-related under Prof Gaspar |
Cell viability (MTT, AlamarBlue, etc.);Hepatotoxicity (HepG2 cells) (In vitro);Cytotoxicity (cancer vs. normal cells) (In vitro);Haemolysis assays (In vitro) |
MMT and LHD assays, CHO, HepG2, HEK293 cells - 2 weeks turnaround. Haemoly |
https://caflabs.org.za/ |
Tyrick Welcome, Natanya Venter, Jessica Thibaud, Terezie Tichakova, Michelle Kok |
|
| 24 |
Mariette van der Watt |
mariette.vanderwatt@up.ac.za
|
South Africa |
|
Malaria biology - transmission |
|
|
|
Malaria - P. falciparum, full panel of drug-sensitive and resistant strains, >100 clinical isolates from southern african origin |
Cell viability (MTT, AlamarBlue, etc.);Hepatotoxicity (HepG2 cells) (In vitro);Cytotoxicity (cancer vs. normal cells) (In vitro);Haemolysis assays (In vitro);Developmental toxicity (In vivo) |
Cell viability (MTT, AlamarBlue, LHD, ATP) - 1 week, HepG2, CHO and HEK293 cells, various cancer cell lines available additionally, haemolysis assay - 1 week, developmental toxicity with zebrafish model |
|
|
|
| 25 |
Mathew Njoroge |
mn.njoroge@uct.ac.za
|
South Africa |
|
Drug Metabolism and Pharmacokinetics |
The H3D drug discovery portfolio is across malaria, TB and AMR, and is underpinned by platforms in medicinal chemistry, biology, DMPK and Artificial Intelligence/Machine learning. |
TB: Malaria; AMR |
Malaria;Tuberculosis (TB);Bacterial assays (e.g., AMR-related) |
Malaria - NF54, K1, 3d7. Dd2 - https://h3d.uct.ac.za/drug-discovery-services/malaria-biology-platform-services TB - H37Rv for routine screening, as well as Erdman strain, SDR strains and target based screens on various mutants - https://h3d.uct.ac.za/drug-discovery-services/tb-biology-services AMR - ESKAPE panel including lab and clinical strains (https://h3d.uct.ac.za/drug-discovery-services/amr-platform-services) |
Cell viability (MTT, AlamarBlue, etc.);Hepatotoxicity (HepG2 cells) (In vitro);Haemolysis assays (In vitro) |
|
https://h3d.uct.ac.za/drug-discovery-services |
|
|
| 26 |
Mwila Mulubwa |
mwila.mulubwa@uct.ac.za
|
South Africa |
|
Pharmacometrics |
DMPK research. I contribute to translational and quantitative pharmacology efforts across a broad spectrum of therapeutic areas, with a particular focus on tuberculosis and malaria. My work involves the application of population pharmacokinetic and pharmacokinetic–pharmacodynamic (PK/PD) modelling, exposure–response analyses, and physiologically based pharmacokinetic (PBPK) approaches to optimize dose selection, guide rational compound progression. By integrating preclinical, clinical, and real-world data, I aim to accelerate drug development pipelines, reduce attrition, and inform precision dosing strategies that enhance the safety and efficacy of novel therapies in diverse patient populations. |
TB: Malaria: AMR |
Malaria;Tuberculosis (TB);Bacterial assays (e.g., AMR-related) |
Malaria - NF54, K1, 3d7. Dd2 - https://h3d.uct.ac.za/drug-discovery-services/malaria-biology-platform-services TB - H37Rv for routine screening, as well as Erdman strain, SDR strains and target based screens on various mutants - https://h3d.uct.ac.za/drug-discovery-services/tb-biology-services AMR - ESKAPE panel including lab and clinical strains (https://h3d.uct.ac.za/drug-discovery-services/amr-platform-services) |
|
|
https://h3d.uct.ac.za/drug-discovery-services |
|
|
| 27 |
Peter Mubanga Cheuka |
peter.cheuka@unza.zm
|
Zambia |
|
Chemistry (Organic Synthesis and Med Chem) |
Malaria and schistosomiasis continue to exert significant morbidity and are responsible for a total of close to 1 million lives every year. Current treatment options, such as the artemisinin-combination therapies (ACTs) and praziquantel are characterized by challenges, among them, rising resistance. In this project, we have been exploring a new class of compounds for their antimalarial and antischistosomal potential. We have synthesized nearly 100 compounds and tested them on Plasmodium falciparum (Pf) and Schistosoma mansoni (Sm), the parasites responsible for malaria and schistosomiasis, respectively. We have identified some compounds with dual activity on the two parasite strains (e.g., for one frontrunner compound, SmEC50 = 0.08 μM (motility assay) and PfEC50 = 2.58 μM (SYBR Green I assay)). The compound exhibited a comfortable selectivity over the human embryonic kidney 293 (HEK 293) cell line (selectivity index = 123) with respect to S. mansoni potency although there is still need to improve potency on P. falciparum parasites. The higher experimental lipophilicity (Log D = 4.67); low aqueous solubility (0.3 μM); and moderate mouse microsomal clearance (CLint = 3.92 mL min-1 g-1) also need to be addressed. Efforts to improve these parameters are ongoing in our group. |
Malaria; Schistosomiasis |
|
|
|
|
|
Ameera Mohammed Dawoodjee, Masebe Kanyanta, Chanda Katongo, Jesse Kasweka, Henry Chalwe, Steve Mbaya, Sarah Mwayani Nampokolwe |
|
| 28 |
Rajshekhar Karpoormath |
karpoormath@ukzn.ac.za
|
South Africa |
|
Chemistry (Synthetic and Medicinal); Natural products (extraction, purification); anticancer screening |
The Synthetic and Medicinal Chemistry Research Group (SMCRG), led by Prof. Rajshekhar Karpoormath at the University of KwaZulu-Natal, focuses on target-based drug design, development of novel small-molecule therapeutics as anti-mycobacterial drugs, anti-malarial and anti antimicrobial compounds, plasmodial inhibitors for malaria, and to combat tuberculosis, |
TB; AMR; Malaria; anticancer screening |
Tuberculosis (TB);Bacterial assays (e.g., AMR-related) |
We have access to the BSL3 facilities and access to MTB stains including resistant and clinical isolates. Similarly we do routine anti-microbial screening against ATCC strains and few resistant strains. |
Cell viability (MTT, AlamarBlue, etc.);Hepatotoxicity (HepG2 cells) (In vitro);Cytotoxicity (cancer vs. normal cells) (In vitro) |
We have the facility to conduct preliminary cytotoxicity studies and also have access to various cancer cell lines to perform anti-cancer screening of compounds. |
|
|
|
| 29 |
Richard Amewu |
ramewu@ug.edu.gh
|
Ghana |
|
Chemistry - Malaria |
|
|
|
|
|
|
|
Dr. Henry A. Onyame, Fritz E. Plange, Justice Akwensi, Deborah Annor, Hagar Afriyie, Zoey Nnenna Ami Fiaxe |
|
| 30 |
Rose Hayeshi |
rose.hayeshi@nwu.ac.za
|
South Africa |
|
Natural Products (Biodiversity sourcing, extraction&fractionation); Toxicology (in vivo); Pharmacology (in vivo); Enzyme inhibition and induction; Formulation Development; Safety pharmacology; Pre-investigational IND-enabling studies; Modelling, Bioninformatics; |
Non-GLP and GLP toxicology in rodents, PK in rodents, efficacy in rodents |
|
|
|
Acute toxicity (In vivo);Sub-acute and chronic studies (In vivo);Reproductive toxicity (In vivo);Developmental toxicity (In vivo);Neurotoxicity and behavioural testing (In vivo) |
3-6 months or more including ethics approval |
https://health-sciences.nwu.ac.za/pcddp |
|
|
| 31 |
Roslyn Thelingwani |
rthelingwani@aibst.edu.zw
|
Zimbabwe |
|
Genomics and transcriptomics; Natural Products (Extraction&Fraction); In vitro ADME (Solubility;lipophilicity; PPB; Met stability; Enzyme Inhibition) |
Pharmacogenomics, biaoanalytical chemistry, dru metabolism and pharmacokinetics, clinical trials |
|
|
|
|
|
|
|
|
| 32 |
Sospter Ngoci |
snjeru@kemri.go.ke
|
Kenya |
|
Drug Metabolism and Pharmacokinetics; Genomics |
|
|
|
|
|
|
|
|
|
| 33 |
Stanley Mukanganyama |
smukanganyama@aibst.edu.zw
|
Zimbabwe |
|
Drug Metabolism and Pharmacokinetics; Genomics |
|
|
|
|
|
|
|
|
|
| 34 |
Susan Winks |
susan.winks@uct.ac.za
|
South Africa |
|
H3D, H3D Foundation Coordination |
H3D pioneers world-class drug discovery in Africa and is known for its breakthrough research on malaria. The Center focuses on discovering novel medicines for infectious diseases that predominantly affect African populations, with malaria, tuberculosis and AMR in its current portfolio. Towards addressing health inequalities, H3D is also developing technology platforms that will allow for the customization of medicines to African patients’ needs. At H3D, African scientists can utilize their scientific skills and education to improve the health of African patients and to educate the next generation of African scientists. |
TB: Malaria; AMR |
|
|
|
|
https://h3d.uct.ac.za/sites/default/files/media/documents/h3d-service-brochure-2025.pdf |
Nicola Elliott-Wong, Godfrey Mayoka |
|
| 35 |
Tayla Rabie |
tayla.rabie@up.ac.za
|
South Africa |
|
Malaria biology |
|
|
|
|
|
|
|
|
|
| 36 |
Vinayak Singh |
vinayak.singh@uct.ac.za
|
South Africa |
|
Tuberculosis biology |
|
|
|
|
|
|
|
|
|
| 37 |
Winston Nxumalo |
winston.nxumalo@ul.ac.za
|
South Africa |
|
Chemistry (Organic synthesis and Med Chem): Natural Products Chemistry |
Organic synthesis and medicinal chemistry research, designing compounds that are evaluated for the biological activities against TB, malaria and cancer. Our group is in collaborations with a number of research groups, which assist with biological assays and computational modelling. |
TB; Malaria; Cancer |
|
|
|
|
|
|
|
